Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (1)
- Anatomy (1)
- Animal Experimentation and Research (1)
- Biochemical Phenomena, Metabolism, and Nutrition (1)
- Biochemistry, Biophysics, and Structural Biology (1)
-
- Bioinformatics (1)
- Biological Phenomena, Cell Phenomena, and Immunity (1)
- Cancer Biology (1)
- Cell Biology (1)
- Cell and Developmental Biology (1)
- Cellular and Molecular Physiology (1)
- Digestive System (1)
- Digestive System Diseases (1)
- Digestive, Oral, and Skin Physiology (1)
- Disease Modeling (1)
- Diseases (1)
- Gastroenterology (1)
- Genetics (1)
- Genetics and Genomics (1)
- Immunity (1)
- Immunology and Infectious Disease (1)
- Immunotherapy (1)
- Laboratory and Basic Science Research (1)
- Life Sciences (1)
- Molecular Biology (1)
- Obstetrics and Gynecology (1)
- Oncology (1)
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
The Role Of The Hypoxia-Inducible Factor 2 In Pancreatic Cancer: Mechanisms Of Tumor Immunosuppression And Intestinal Radioprotection, Carolina Garcia Garcia
The Role Of The Hypoxia-Inducible Factor 2 In Pancreatic Cancer: Mechanisms Of Tumor Immunosuppression And Intestinal Radioprotection, Carolina Garcia Garcia
Dissertations & Theses (Open Access)
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with dismal prognosis. The only curative option for patients is surgery, but over 80% of patients are not surgical candidates. Unfortunately, PDAC is resistant to the three remaining options. PDAC is characterized by a profoundly hypoxic and immunosuppressive stroma, which contributes to its therapeutic recalcitrance. Alpha-smooth muscle actin+ (αSMA+) cancer-associated fibroblasts (CAFs) are the most abundant stromal component, as well as mediators of stromal deposition. The hypoxia-inducible factors (HIF1 and HIF2) coordinate responses to hypoxia, yet, despite their known association to poor patient outcomes, their functions within the PDAC tumor microenvironment (TME) …
Targeting Metabolic Adaptations To Anti-Angiogenic Therapy In Ovarian Cancer, Deanna M. Glassman, Deanna Glassman
Targeting Metabolic Adaptations To Anti-Angiogenic Therapy In Ovarian Cancer, Deanna M. Glassman, Deanna Glassman
Dissertations & Theses (Open Access)
ABSTRACT
Background: Ovarian cancer is the most lethal gynecologic malignancy. Despite modest clinical improvements with anti-VEGF antibody (AVA) therapy, adaptive resistance is nearly ubiquitous and additional therapeutic options are limited. A dependence on glutamine metabolism, via the enzyme glutaminase (GLS), is a known mechanism of adaptive resistance.
Purpose: To assess the efficacy of a glutaminase inhibitor as a means of exploiting the metabolic vulnerability of glutamine dependence that develops as a result of adaptive resistance to AVA therapy.
Experimental Design: We used a glutaminase inhibitor (GLSi) synthesized at MD Anderson Cancer Center for all in vitro and in vivo experiments. …